Please assess the completion status of the following clinical trial:

Trial Title: Growth Hormone and Glucose Metabolism

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients \>18 years old.~* Severe GH deficiency as diagnosed by an inadequate GH stimulation in three different tests:~  1. peak response \< 3 µg/l during an insulin tolerance test;~ 2. \< 3 µg/l during glucagon test;~ 3. \< 9 µg/l during GHRH-arginine stimulation test).~Exclusion Criteria:~* GH replacement therapy prior to inclusion.~* History of diabetes Type 1 or 2.~* Biochemical evidence of impaired hepatic or renal function.~* History of cardiovascular disease.~* Uncontrolled hypertension.~* Current inflammatory or malignant disease.~* Pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Growth Hormone (Type: EXPERIMENTAL): Therapy with recombinant human GH (Genotropin® 1 mg = 3 IU, Pfizer Inc., NY, USA) daily by subcutaneous injection using a Genotropin pen at maximal GH dose of 0.003 mg/kg/day in patients with severe GHD

Based on this trial design, predict the completion outcome and termination type (if applicable).